Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Related to this article
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Dr Geyer on the FDA Approval of Post-Neoadjuvant T-DXd for HER2+ Breast Cancer
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD
4
Dr Vachhani on Phase 2 Efficacy/Safety Data for Sapablursen in Polycythemia Vera
5